24-06-2025
JonesTrading Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)
JonesTrading analyst Catherine Novack maintained a Buy rating on Larimar Therapeutics (LRMR – Research Report) yesterday and set a price target of $12.00. The company's shares closed yesterday at $2.42.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Novack covers the Healthcare sector, focusing on stocks such as Larimar Therapeutics, Capricor Therapeutics, and Regulus. According to TipRanks, Novack has an average return of 7.5% and a 27.88% success rate on recommended stocks.
Larimar Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.43.
